Human Glycoprotein IIb/IIIa Receptor Monoclonal Antibody
Produktgrößen
1 mg
£486,00
YR0105-1MG
5 mg
£1355,00
YR0105-5MG
20 mg
£3531,00
YR0105-20MG
Über dieses Produkt
- SKU:
- YR0105
- Anwendung:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Klonalität:
- Monoclonal
- Weitere Details:
- Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab.Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- glycoprotein (GP) IIb/IIIa
- Isotyp:
- IgG1, kappa
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- ABclonal Technology
- Typ:
- Antibody: Biosimilar Antibody
- Datenblatt des Herstellers:YR0105